List of Excipients in Branded Drug ZTLIDO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Scilex Pharmaceuticals Inc	ZTLIDO	lidocaine	69557-111	BUTYLATED HYDROXYTOLUENE
Scilex Pharmaceuticals Inc	ZTLIDO	lidocaine	69557-111	DIPROPYLENE GLYCOL
Scilex Pharmaceuticals Inc	ZTLIDO	lidocaine	69557-111	ISOSTEARIC ACID
Scilex Pharmaceuticals Inc	ZTLIDO	lidocaine	69557-111	MINERAL OIL
Scilex Pharmaceuticals Inc	ZTLIDO	lidocaine	69557-111	POLYISOBUTYLENE

ZTlido Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

ZTlido is a prescription lidocaine topical system designed for postherpetic neuralgia. Its commercial differentiation depends less on the active ingredient than on the delivery system: a 1.8% lidocaine adhesive patch that is intended to remain in place during use, deliver local analgesia, and reduce the practical limitations associated with older lidocaine patches. The main excipient opportunity is to improve adhesion, skin tolerability, drug release, wear time, and manufacturing economics without triggering a new clinical or regulatory burden.

What is ZTlido and how does its formulation work?

ZTlido contains 36 mg of lidocaine in each topical system, corresponding to a 1.8% lidocaine formulation. It is applied to intact skin for up to 12 hours within a 24-hour period, with a maximum of three systems applied simultaneously under the FDA labeling. Its approved indication is the relief of pain associated with postherpetic neuralgia. [1]

The product is an adhesive drug-in-adhesive system. Lidocaine is incorporated directly into a pressure-sensitive adhesive matrix rather than being held in a liquid reservoir. The adhesive must perform several functions at once:

Formulation function	Commercial relevance
Maintain contact with skin	Reduces early detachment and replacement
Control lidocaine release	Supports local analgesia while limiting systemic exposure
Tolerate movement and perspiration	Improves patient adherence
Remove cleanly	Reduces residue and skin trauma
Maintain drug uniformity	Supports dose consistency and manufacturing control
Protect the product during storage	Supports shelf life and distribution

The FDA label identifies the product’s inactive adhesive-system materials as including polyisobutylene, styrene-isoprene-styrene block copolymer, hydrogenated rosin ester, and mineral oil. The system also includes a backing layer and release liner. [1]

What excipients are used in ZTlido?

ZTlido’s excipient platform is based on a nonaqueous pressure-sensitive adhesive. Each component has a defined technical role.

Polyisobutylene

Polyisobutylene is a primary tackifying and matrix-forming polymer. It can provide skin contact without relying on water evaporation or solvent evaporation during use. Its low chemical reactivity is useful for a product intended for repeated application to potentially sensitive skin.

Its commercial value comes from the balance between adhesion and skin tolerability. A formulation with insufficient polyisobutylene may detach prematurely. Excessive tack can increase removal pain, residue, or epidermal stripping.

Styrene-isoprene-styrene block copolymer

Styrene-isoprene-styrene is an elastomeric block copolymer that contributes cohesion and mechanical strength. It can help the adhesive stretch with movement while resisting tearing or adhesive transfer.

For a topical system, cohesion is as important as tack. A formulation that adheres strongly but breaks apart during removal can create manufacturing, handling, and patient-use problems.

Hydrogenated rosin ester

Hydrogenated rosin ester is a tackifying resin. It increases adhesion to the skin and can improve initial tack after application. Hydrogenation can improve oxidative stability compared with less-stable resin systems.

The main development issue is concentration control. Tackifier levels affect adhesion, residue, skin stripping, and the interaction between lidocaine and the adhesive matrix.

Mineral oil

Mineral oil acts as a plasticizing or softening component. It can improve flexibility and reduce brittleness in the adhesive layer. It also changes the mobility of lidocaine within the matrix and can influence drug release.

The formulation risk is migration. Excessive plasticizer movement can affect adhesive performance, drug crystallization, liner release, and long-term stability.

How does ZTlido’s excipient strategy differ from Lidoderm?

ZTlido competes primarily with generic lidocaine 5% patches and branded or authorized-generic versions of Lidoderm. The active pharmaceutical ingredient is the same, but the delivery systems differ.

Attribute	ZTlido	Lidoderm and generic lidocaine 5% patches
Active ingredient	Lidocaine	Lidocaine
Nominal drug strength	1.8%	5%
Delivery architecture	Drug-in-adhesive topical system	Topical patch with a distinct drug-containing adhesive architecture
Approved use	Postherpetic neuralgia	Postherpetic neuralgia
Maximum labeled use	Up to three systems for 12 hours in 24 hours	Commonly up to three patches for 12 hours in 24 hours, depending on labeling
Primary differentiation	Adhesion, handling, and wear performance	Established clinical history and generic availability
Main commercial weakness	Higher branded-product price	Lower price and broad generic access

The lower nominal lidocaine concentration does not, by itself, establish lower clinical value. The commercial argument is that the drug delivery system can improve real-world use by keeping the system in contact with the skin and reducing product failure caused by detachment.

This distinction is important for excipient strategy. A generic developer does not need to duplicate the exact qualitative or quantitative composition if it can demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway. A branded competitor, however, can use new adhesive materials to pursue a separate product profile, such as improved sweat resistance or less traumatic removal.

What formulation attributes create the strongest commercial opportunity?

Adhesion during activity

Patients with postherpetic neuralgia may apply topical systems to the torso, back, or other areas subject to movement. Adhesion during sweating, clothing friction, and repositioning is a commercially meaningful differentiator.

Potential development targets include:

• Higher shear resistance during movement
• Better adhesion under humid conditions
• Less edge lifting
• Consistent adhesion over 12 hours
• Better performance on contoured body surfaces

The formulation must avoid solving adhesion problems by simply increasing tack. Excessive tack may increase skin irritation and make removal difficult.

Low-residue removal

Adhesive residue affects patient satisfaction, caregiver acceptance, and repeat use. A system that leaves substantial polymer or resin on the skin can require cleaning and may reduce willingness to use the product.

Potential excipient opportunities include:

• Lower-transfer tackifier systems
• Surface-modified adhesives
• Silicone or hybrid adhesive technologies
• Controlled-release liners
• Adhesive systems designed for clean peel behavior

Any replacement must preserve drug uniformity and release characteristics.

Skin tolerability

Repeated exposure is central to the product’s use pattern. The most valuable excipient improvements may involve reduced erythema, itching, and mechanical skin trauma rather than greater lidocaine flux.

A commercially attractive formulation would maintain adhesion while reducing:

• Local irritation
• Sensitization risk
• Epidermal stripping
• Residue
• Pain on removal

Excipient selection must also account for sensitizing impurities, residual monomers, peroxide levels, extractables, and leachables from backing and liner materials.

Stable lidocaine dispersion

Lidocaine can crystallize or redistribute in an adhesive matrix during storage. Crystallization can reduce effective release, create content-uniformity concerns, and alter product appearance.

The excipient system should control:

• Lidocaine solubility in the adhesive
• Crystal nucleation
• Drug migration
• Water uptake
• Adhesive modulus
• Release rate over the labeled wear period

This area creates opportunities for formulation patents because small changes in polymer grade, tackifier ratio, plasticizer concentration, or processing conditions can materially affect product performance.

What patents protect ZTlido?

ZTlido has multiple potential protection layers:

1. Drug-in-adhesive composition claims.
2. Lidocaine topical-system claims.
3. Adhesive-polymer and tackifier combinations.
4. Manufacturing-process claims.
5. Packaging and stability claims.
6. Method-of-use claims for treating localized neuropathic pain.

The FDA Orange Book is the controlling public source for patents listed against an approved drug product. ZTlido is approved under NDA 209958, and its Orange Book status should be reviewed by patent number, use code, and expiration date rather than by relying on a single product patent. [2]

The most important patent question is whether the relevant claims cover the commercial product as a combination of:

• Lidocaine concentration
• Adhesive composition
• Layer construction
• Wear-time performance
• Manufacturing conditions
• Intended method of use

A narrow composition claim may be vulnerable to a non-infringing adhesive design. A broader claim directed to the functional combination of lidocaine and a defined pressure-sensitive adhesive may create a stronger barrier, but its validity may depend on written description, enablement, obviousness, and prior-art adhesive systems.

When does ZTlido lose exclusivity?

ZTlido’s regulatory exclusivity and patent exclusivity are separate.

FDA exclusivity

ZTlido was approved by the FDA in February 2018. [1] The approval was for a small-molecule prescription product, not a biologic. The product therefore does not receive biologic reference-product exclusivity, and biosimilar law does not apply.

The relevant generic pathway is an Abbreviated New Drug Application, typically involving a Paragraph IV certification if an ANDA applicant contends that an Orange Book-listed patent is invalid, unenforceable, or not infringed. [3]

Patent expiration

The effective generic-entry date depends on:

• Orange Book-listed patents
• Patent-term adjustment
• Patent-term extension, if any
• Paragraph IV litigation
• Thirty-month stays
• Court injunctions
• Settlement agreements
• ANDA approval timing
• Any authorized-generic arrangement

A definitive ZTlido loss-of-exclusivity date cannot be inferred from the FDA approval date alone. The Orange Book patent listing and current court docket must be read together. [2]

What Paragraph IV challenges and litigation affect ZTlido?

A generic applicant can file an ANDA with a Paragraph IV certification against a listed ZTlido patent. The patent holder may then file an infringement action within 45 days, triggering a statutory stay of FDA approval for up to 30 months, subject to court actions and statutory exceptions. [3]

The key litigation questions are:

Issue	Business impact
Which patent claims are certified against?	Defines the technical design-around requirement
Is the use code narrow or broad?	Determines the scope of method-of-use risk
Does the case concern adhesive composition or product configuration?	Determines whether a non-infringing formulation is feasible
Is a 30-month stay triggered?	Delays ANDA approval
Is there an agreed settlement date?	Establishes potential generic entry
Is an authorized generic launched?	Changes price erosion and market-share dynamics

Patent litigation involving topical systems can be technically intensive. The decisive evidence may include adhesive rheology, peel and shear data, drug-distribution microscopy, dissolution or release testing, manufacturing records, and comparative skin-adhesion studies.

What generic entry risks exist for ZTlido?

The generic threat is structurally significant because lidocaine is an established small-molecule active ingredient and generic manufacturers can compete through a topical-system ANDA.

The most credible entry scenarios are:

Single first-filer entry

One applicant files a Paragraph IV certification and obtains 180-day exclusivity if it qualifies as the first substantially complete ANDA applicant and satisfies the statutory conditions. The first filer may launch at a moderate discount before broader generic entry.

Multiple generic launches

Once first-filer exclusivity is forfeited or expires, several manufacturers may enter. Topical systems can experience rapid price compression because the active ingredient is inexpensive and the market is familiar with generic lidocaine products.

Authorized generic

An authorized generic or licensed alternative can reduce the commercial impact of independent ANDA entry. The branded manufacturer can retain supply-chain control while accepting lower per-unit pricing.

Formulation challenge

If the core ZTlido patent estate is composition-focused, a generic may design around the specific adhesive combination while preserving the same active ingredient and route of administration. This is the principal technical risk to a formulation-led exclusivity strategy.

What commercial opportunities exist for ZTlido excipients?

Premium prescription positioning

ZTlido can continue to target patients for whom patch adherence, comfort, or handling is more important than the lowest acquisition cost. Payer coverage and step-edit requirements will determine how much of this premium can be retained.

Next-generation topical systems

The excipient platform can be adapted to products with:

• Longer wear periods
• Lower skin irritation
• Improved use during exercise or sweating
• Smaller patch dimensions
• More flexible backing materials
• Lower residue
• Pediatric or geriatric handling advantages

A new product would need a clear clinical or practical benefit. A minor excipient change without measurable patient value is unlikely to support a durable premium.

Combination topical products

The adhesive technology may support combinations involving other local anesthetics, anti-inflammatory agents, or neuropathic-pain drugs. Combination products create new clinical, regulatory, and patent requirements. They also increase the risk of drug-drug interactions within the adhesive matrix.

Contract formulation and licensing

Excipient suppliers with pressure-sensitive adhesive expertise can pursue licensing or supply agreements based on:

• Proprietary tackifier systems
• Low-irritation polymer blends
• Drug-crystallization control
• Skin-compatible plasticizers
• High-barrier backing films
• Specialized release liners

The strongest licensing assets are not generic excipients alone. They are excipient combinations supported by reproducible manufacturing data, stability data, skin-adhesion data, and freedom-to-operate analysis.

Hospital and specialty-pharmacy channels

A reliable topical system may have value in specialty pain clinics, postherpetic-neuralgia programs, and settings where caregiver application matters. Hospital formulary adoption is more likely when the product demonstrates lower replacement frequency, better patient compliance, or reduced nursing time.

How strong is the ZTlido patent estate?

The estate should be viewed as moderately defensible if it contains claims covering the commercial adhesive matrix and manufacturing process, but more vulnerable if protection is limited to broad concepts such as topical lidocaine patches.

Strength indicators include:

• Claims directed to the specific drug-in-adhesive composition
• Demonstrated unexpected adhesion or release performance
• Multiple patent families with different expiration dates
• Manufacturing claims that are difficult to design around
• Validated stability advantages
• Narrow but enforceable method-of-use claims

Weakness indicators include:

• Heavy reliance on predictable adhesive substitutions
• Prior art covering common lidocaine patch architectures
• Narrow claims tied to one polymer grade or concentration range
• Lack of measurable performance advantages
• Easy substitution of tackifiers or plasticizers
• Patent claims that do not map closely to the marketed product

The commercial value of the estate will depend on whether a competitor can produce an equivalent topical system using a different adhesive architecture.

What is the FDA and Orange Book status of ZTlido?

ZTlido is an FDA-approved prescription drug product under NDA 209958 for postherpetic neuralgia. It is a small-molecule topical system, not a biologic, so biosimilar competition is irrelevant. [1]

The Orange Book should be used to confirm:

• Listed patents
• Patent expiration dates
• Use codes
• Delisting activity
• Any patent-term adjustment
• Current reference-listed-drug status

The Orange Book does not by itself establish whether a patent will survive litigation or when a generic will launch. Those questions require review of Paragraph IV notices, district-court filings, FDA ANDA actions, and settlement terms.

Key Takeaways

• ZTlido’s commercial differentiation is primarily its adhesive drug-delivery system, not lidocaine itself.
• The disclosed excipient strategy uses polyisobutylene, styrene-isoprene-styrene block copolymer, hydrogenated rosin ester, and mineral oil in a pressure-sensitive adhesive matrix.
• The highest-value formulation objectives are sustained adhesion, clean removal, low irritation, and stable lidocaine dispersion.
• Generic competition is likely to target the adhesive system through ANDA and Paragraph IV pathways.
• ZTlido has no biosimilar risk because it is a small-molecule product.
• Formulation patents are most valuable when they cover measurable performance advantages and manufacturing conditions that are difficult to design around.
• Commercial growth opportunities include next-generation low-irritation systems, longer-wear products, combination topicals, and excipient licensing.
• The definitive exclusivity analysis requires the current Orange Book listing and active litigation record, not the FDA approval date alone.

FAQs

Can ZTlido excipients be substituted by a generic manufacturer?

Yes. An ANDA applicant generally does not need to duplicate every inactive ingredient if the proposed product satisfies applicable pharmaceutical-equivalence, bioequivalence, quality, and labeling requirements. The applicant must also address any patent claims that cover the formulation or use.

Could a silicone adhesive replace ZTlido’s polymer adhesive?

Potentially, but a replacement would require development work addressing lidocaine solubility, release, adhesion, skin tolerability, liner removal, stability, and manufacturing scale-up. A silicone adhesive could also create a distinct patent position if it produces a non-obvious performance benefit.

Is ZTlido eligible for over-the-counter switching?

A switch would require FDA review of safety, self-selection, labeling comprehension, dosing, and use conditions. The existing prescription indication for postherpetic neuralgia does not create an automatic OTC pathway.

Do excipient changes require a new FDA application?

The regulatory consequence depends on the magnitude of the change. Minor changes may be handled through an approved post-approval supplement, while major changes to the adhesive system, drug release, dosage form, or clinical performance may require substantial additional studies or a new application strategy.

What is the most attractive excipient licensing opportunity around ZTlido?

The strongest opportunity is a validated adhesive platform that improves wear time and skin tolerability while preserving lidocaine release and manufacturing scalability. A formulation package supported by comparative data and patent claims has greater licensing value than an unprotected commodity polymer.

References

1. U.S. Food and Drug Administration. (2018). ZTlido (lidocaine) topical system prescribing information. Scilex Pharmaceuticals Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). ANDA submissions: Amendments and requests for final approval to tentatively approved ANDAs. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug product exclusivity and patent listing requirements. FDA.